ArticleInternational journal of clinical and experimental pathology2019
EFEMP2 promotes colon cancer cell invasion and growth through the ERK1/2 signaling pathway.
Article in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- Construction of store-operated calcium entry-related gene signature for predicting prognosis and indicates immune microenvironment infiltration in stomach adenocarcinomas.Scientific reports · 2024Article
- ZNF714 Supports Pro-Oncogenic Features in Lung Cancer Cells.International journal of molecular sciences · 2023Article
- Potassium voltage‑gated channel subfamily E member 4 facilitates the malignant progression of colon cancer by enhancing EGF containing fibulin extracellular matrix protein 2 expression.Experimental and therapeutic medicine · 2023Article
- Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.Stem cell research & therapy · 2022Article
- Classification of colon adenocarcinoma based on immunological characterizations: Implications for prognosis and immunotherapy.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
EFEMP2 is an extracellular matrix (ECM) glycoprotein that is a pivotal oncogene in tumor progression and metastasis. However, the function of EFEMP2 in colon cancer remains unknown. In this study, we found that EFEMP2 was highly expressed in colon cancer cells. Knockdown of EFEMP2 suppressed the growth and invasion of colon cancer LoVo and SW620 cells. Moreover, knockdown of EFEMP2 attenuated ERK1/2 activation, as well as decreased MMP-3 expression. Taken together, our study demonstrates that EFEMP2 is significantly expressed in colon cancer cells. EFEMP2 can promote the growth and invasion of colon cancer cells, possibly by regulation of ERK1/2 activation and MMP-3 expression. Therapies targeting EFEMP2 may be an effective strategy for treatment of colon cancer.
Indexed as
Identifiers
31933893PMC6945161W3007087554What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.